Chugai Pharmaceutical stock pre-market at EUR 34.32: plus 0.18 percent
Published on 10/07/2026 at 08:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Chugai Pharmaceutical stock was at EUR 34.32 pre-market at 8:01 a.m. CEST on October 7, 2026, at Lang & Schwarz. That was plus 0.18 percent versus the Lang & Schwarz prior close of EUR 34.26 on October 6, 2026.
Pre-market price
The Lang & Schwarz indication put Chugai Pharmaceutical EUR 0.06 above the prior close. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.
Previous trading reference
The previous Lang & Schwarz closing price was EUR 34.26 on October 6, 2026. Chugai Pharmaceutical is identified as TSE:4519 in the company market information.
Emugrobart development
A JPX Market Explorer entry dated September 28, 2026, reported that Chugai Pharmaceutical would discontinue clinical development of emugrobart, also known as GYM329, for obesity after Roche ended further development. The report said rights previously licensed to Roche would return to Chugai, which had begun preparing to resume development for spinal muscular atrophy and was considering potential out-licensing opportunities.
The report said the obesity decision followed an assessment of data from the Phase II GYMINDA study. It stated that achieving the study's predefined efficacy objectives for clinically meaningful weight loss was considered unlikely, while emugrobart was well tolerated and no new safety signals were observed.
